Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Views - The company's performance met expectations, with a focus on the anti-aging agent industry reaching a bottom and the upcoming increase in lubricant additive volume [1][2]. - The company is expanding its overseas market presence, with high-end products accounting for a growing share of sales, leading to an increase in revenue and profit margins [7]. - The second phase of the Kangtai project is gradually releasing capacity, contributing to performance growth, while the lubricant additive business is expected to benefit from global supply chain restructuring [7]. - The life sciences business is being pushed to market, with electronic-grade PI business accelerating integration domestically and internationally, opening new growth avenues [7]. - The profit forecast has been adjusted downwards for 2025-2026 due to trade disruptions and weak terminal demand, with new profit estimates for 2027 introduced [7]. Financial Data and Profit Forecast - Total revenue is projected to reach 6,559 million in 2025, with a year-on-year growth rate of 15.3% [3]. - Net profit attributable to the parent company is expected to be 585 million in 2025, reflecting a year-on-year growth of 37.2% [3]. - Earnings per share are forecasted to be 2.55 yuan in 2025, with a gross margin of 22.4% [3]. - The return on equity (ROE) is projected to be 11.8% in 2025, with a price-to-earnings (PE) ratio of 12 [3]. Market Data - As of May 20, 2025, the closing price of the stock is 29.92 yuan, with a market capitalization of 6,723 million [4]. - The stock has a price-to-book (PB) ratio of 1.5, indicating a relatively high safety margin compared to its historical average [4][7].

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 29.54 RMB [5][6]. Core Views - The company reported a steady performance in Q1 2025, achieving revenue of 1.5 billion RMB, with a quarter-on-quarter increase of 9% and a year-on-year increase of 4%. The net profit attributable to shareholders was 100 million RMB, showing a slight quarter-on-quarter increase of 0.7% but a year-on-year decrease of 4% [1]. - The company is expected to have growth potential due to the gradual ramp-up of new projects and the ongoing industrialization of electronic-grade PI and life sciences sectors [1]. - The company is expanding its market presence, particularly in the lubricant additive sector, with a focus on internationalization through the establishment of a research and production base in Malaysia [2]. - The life sciences segment has shown significant progress, with a pilot workshop for nucleic acid monomers and partnerships with nearly 90 clients, indicating a strong market transition from R&D to dual-track operations [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 21.52% in Q1 2025, remaining stable compared to previous periods. The comprehensive expense ratio was 12%, with a slight increase attributed to higher R&D expenses [2]. - The forecast for net profit attributable to shareholders for 2025-2027 is 480 million, 530 million, and 580 million RMB, respectively, with year-on-year growth rates of 14%, 10%, and 10% [4]. Market Expansion - The company is actively exploring new markets, with a notable 15% increase in lubricant additive exports from Liaoning province in Q1 2025 [2]. - The establishment of a production base in Malaysia is expected to enhance the company's international competitiveness and risk resilience [2]. Business Development - The life sciences segment has made strides with the introduction of the phosphoramidite monomer into the supply chain of downstream clients, and the dNTP products have reached advanced domestic levels with over 70 client collaborations [3]. - The company has completed the acquisition of Yixing Chuangju and is set to supply flexible display leaders in bulk by 2025, indicating a robust growth trajectory in the polyimide sector [3].